Latest Content

Clinical trial results showed favorable results with Keytruda-based therapy in this ovarian cancer population.

Clinical trial data support the use of Imdelltra as a standard of care for all patients with second-line small cell lung cancer.

Lymphoma survivors with chronic fatigue participating in a multidisciplinary intervention program experienced benefits to fatigue and quality of life.

Among patients with solid tumors, baseline emotional functioning was moderate, with lower functioning for female and younger patients.

In patients with extensive-stage small cell lung cancer Imdelltra plus chemoimmunotherapy was associated with positive outcomes.

In patients with ER-positive, HER2-negative advanced breast cancer, giredestrant and Afinitor reduced risk of disease progression or death.

Among patients with EGFR-mutated non-small cell lung cancer Tagrisso plus chemotherapy was associated with an improvement in survival.

For patients with HRRm prostate cancer receiving Akeega with prednisone, quality of life remained at baseline.

Ponsegromab improved body weight, suppressed GDF-15 and was well-tolerated over 64 weeks in cancer-associated cachexia, including patients switching from placebo.

Among patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma that is resectable, Imfinzi with FLOT improved survival.

Adding Imfinzi to Bacillus Calmette-Guérin therapy improved disease-free survival for patients with high-risk, non-muscle invasive bladder cancer.

Among patients with muscle-invasive bladder cancer, perioperative Imfinzi to chemotherapy doesn’t have a detrimental effect on patient-reported outcomes.

Lenvima and Keytruda with chemo did not help patients with metastatic esophageal squamous cell carcinoma live longer than Keytruda and chemotherapy alone.